

0

11 November 2021 | News

Merck has been investing at risk to support development and scale-up production of molnupiravir

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine.

Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck's applications for the potential authorized use of molnupiravir are under review by Japan's Pharmaceuticals and Medical Devices Agency, the U.S. Food and Drug Administration, and the European Medicines Agency.

Molnupiravir is authorized in the United Kingdom for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.

Under the agreement, if molnupiravir receives authorization or approval by Japan's Pharmaceuticals and Medical Devices Agency, Merck will supply approximately 1.6 million courses of molnupiravir to the Japanese government for approximately \$1.2 billion including applicable taxes.

In anticipation of results from the Phase 3 MOVE-OUT clinical trial, and the potential for regulatory authorization or approval, Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to produce 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.